Work

iDICss robustly predicts melanoma immunotherapy response by synergizing genomic and transcriptomic knowledge via independent component analysis

Year: 2025

Type: article

Abstract: iDICss robustly predicts melanoma immunotherapy response by synergizing genomic and transcriptomic knowledge via independent component analysisDear Editor, Here, we present a tool named iDIC-based scoring system (iDICss) that is useful for predicting immunotherapy response and prognostic outcomes in melanoma patients.The core principle of the tool is that specific driver alterations affecting the immuno-related gene expression and functions, 1 may be indicative of high tumour mutation burden, a good predictor used to guide immunotherapy decisions in clinical, 2 and analysis of such interplays may provide novel strategies to improve prediction of immunotherapy response.This tool thereby builds on an immune driver independent components (iDICs) profile, which innovatively integrates the immunogenic properties into transcriptome using the independent component analysis (ICA), a popular matrix decomposition method.Optimized by comparison of multiple machine-learning models, an iDICss was established, which exhibits a superior performance of prognostic and immune response prediction compared with other published state-of-art biomarkers.Our study provides a novel strategy to improve the prediction of immunotherapy response for melanoma, which could be adaptable in numerous clinical prediction situations.Melanoma is a highly aggressive skin cancer originating from melanocyte transformation, and its incidence has been increasing globally in recent years.3 Immune checkpoint blocking immunotherapy is one of the most advanced treatment strategies and significantly improves the survival outcomes for melanoma sufferers.However, high genetic heterogeneity of melanoma results in immune responses occurring in only a small proportion of patients, 4-6 which motivates us to explore a robust biomarker to predict patients' immunotherapy response and guide treatment decision.Accumulated studies demonstrate that oncogenic driver mutations shape tumor immune microenvironment (TIME), and cause impediments to immunotherapy.7-9 Hence, the crosstalk

Source: Clinical and Translational Medicine

DOI: 10.1002/ctm2.70183

Authors: Jiayue Qiu, Nana Jin, Lixin Cheng, Chen Huang

Institutions: Macau University of Science and Technology, Southern University of Science and Technology, ShenZhen People’s Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,470